89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive

See also
Status	Clinical Trial	Phase
Completed	`NCT03330561` - PRS-343 in HER2-Positive Solid Tumors	Phase 1
Recruiting	`NCT05523947` - Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor	Phase 1/Phase 2
Completed	`NCT03650348` - PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors	Phase 1

See also

Status

Clinical Trial

Phase

Completed

NCT03330561 - PRS-343 in HER2-Positive Solid Tumors

Phase 1

Recruiting

NCT05523947 - Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Phase 1/Phase 2

Completed

NCT03650348 - PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Phase 1

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04757090
Study type	Interventional
Source	Washington University School of Medicine
Contact
Status	Withdrawn
Phase	Phase 2
Start date	December 31, 2021
Completion date	December 31, 2023

89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms